• Have histologically or cytologically confirmed diagnosis of neoplasia

• Measurable (per RECIST v1.1 criteria) metastatic cancer or locally advanced refractory/recurrent malignancy not amenable to curative treatment. Lesions previously irradiated may be considered measurable only if growth has been documented since local treatment completion.

• The tumor expresses ESO as assessed immunohistochemistry of resected tissue. To this end, archived tumor tissue suitable for analysis must be available or re-biopsy performed on study. Tissue staining must encompass more than 10% of tumor section.

• Patients must have previously either (1) received at least first-line or second-line standard therapy for metastatic disease, if known to be effective for that disease, and have been either non-responders (progressive disease), intolerable or have recurred or (2) Recurred within 6 months of adjuvant systemic therapy known to be active also in the metastatic setting.

• Patients with 3 or fewer brain metastases that are less than 1 cm in diameter and asymptomatic are eligible. Lesions that have been treated with stereotactic radiosurgery must be clinically stable for 1 month after treatment for the patient to be eligible. Patients with surgically resected brain metastases are eligible.

• More than four weeks must have elapsed since any prior systemic therapy at the time the patient receives the preparative regimen, and patients' toxicities must have recovered to a grade 1 or less (except for toxicities such as alopecia or vitiligo).

• Age ≥ 18 years and ≤ 70 years.

• Patient is able to understand and willing to sign a written informed consent.

• Clinical performance status of ECOG 0, 1 or 2.

⁃ HLA-A\*0201or A\*0206 positive.

⁃ Patients of both genders must be willing to practice birth control from the time of enrollment on this study and for four months after treatment.

⁃ Women of child-bearing potential must have a negative pregnancy test.

⁃ Serology: Seronegative for HIV antibody, hepatitis B antigen, and hepatitis C antibody. If hepatitis C antibody test is positive, then patient must be tested for the presence of antigen by RT-PCR and be HCV RNA negative.

⁃ Hematology

∙ ANC \> 1500/mm3 without the support of filgrastim

‣ WBC ≥ 3000/mm3

‣ Platelet count ≥ 100,000/mm3

‣ Hemoglobin \> 8.0 g/dL. Subjects may be transfused to reach this cut-off.

⁃ Chemistry

∙ Serum ALT/AST ≤ 2.5 x ULN

‣ Creatinine clearance ≥40ml/min

‣ Total bilirubin ≤ 1.5 mg/dL, except in patients with Gilbert's Syndrome, who must have a total bilirubin \< 3.0 mg/dL.

‣ INR \< 1.5